Small cap Biomed Realty Trust Inc (NYSE: BMR) is a real estate investment trust (REIT) offering an alternative way to gain exposure to the biotech or life sciences sector, meaning it might be worth taking a closer look at it along with a few benchmarks like the Vanguard REIT ETF (NYSEARCA: VNQ), iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI). Of course, it should be mentioned that REITs have had a rough ride lately�given all the ��apering��talk, but there is still a place for them in your portfolio with Biomed Realty Trust being one of the more unique offerings.
What is Biomed Realty Trust Inc?Small cap Biomed Realty Trust is a fully integrated, self-administered and self-managed�REIT focused on providing real estate to the life science industry. Biomed Realty Trust has�over $5.0 billion invested in state-of-the-art research facilities and a world-class portfolio of life science buildings concentrated in the seven core�US life science markets of Boston, San Francisco, San Diego, Maryland, New York/New Jersey, Pennsylvania and Seattle.
Top 5 Healthcare Equipment Stocks To Invest In Right Now: Celsion Corporation(CLSN)
Celsion Corporation, an oncology drug development company, develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company is developing its lead product, ThermoDox that is in Phase III clinical trial for primary liver cancer; and in phase II clinical trial for treatment of recurrent chest wall breast cancer. It has a license agreement with Yakult Honsha to commercialize and market ThermoDox for the Japanese market. The company also has a license agreement with Duke University under which it received exclusive rights to commercialize and use Duke's thermo-liposome technology. In addition, Celsion Corporation has a joint research agreement with Royal Phillips Electronics to evaluate the combination of Phillips' high intensity focused ultrasound with its ThermoDox to determine the potential of this combination to treat a range of cancers. The company was founded in 1982 and is based in Columbia, M aryland.
Advisors' Opinion:- [By EquityOptionsGuru]
The Prolieve Thermodilatation System was actually developed by the current management of Medifocus while employed at Celsion Corporation (NASDAQ:CLSN). The system was also jointly developed with Boston Scientific (NYSE:BSX) before being acquired by Medifocus in July 2012. Prolieve has already received FDA approval, is currently generating revenue, and is the only in office alternative to drug therapy. The system essentially uses microwave energy to treat Benign Prostatic Hyperplasia (BPH), which is a non-cancerous enlargement of the prostate gland that typically affects men over the age of 50. The Prolieve device works by compressing and heating prostatic tissue that may be blocking the flow of urine. This particular treatment option offers patients several benefits including the following:
- [By Paul Ausick]
Stocks on the Move: NQ Mobile Inc. (NYSE: NQ) is up 26% at $11.09 as the company fights back against a short-seller report. Celsion Corp. (NASDAQ: CLSN) is up 339.3% at $5.14 following a reverse 1:4.5 stock split. Micron Technology Inc. (NASDAQ: MU) is up 4.7% at $17.50.
Best Life Sciences Companies To Invest In Right Now: SanDisk Corporation(SNDK)
Sandisk Corporation designs, develops, and manufactures NAND flash memory storage solutions that are used in various consumer electronics products. The company offers removable cards under the SanDisk Ultra, SanDisk Extreme, and SanDisk Extreme PRO brands; embedded products under the iNAND brand; universal serial bus (USB) flash drives under the Cruzer brand; digital media players under the Sansa brand; solid state drives under the Lightning brand; and wafers and memory components. Its removable card products are used in a range of consumer electronics devices, including mobile phones, digital cameras, gaming devices, and laptop computers; and embedded flash products are used in mobile phones, tablets, ultrabooks, eReaders, global positioning system devices, gaming systems, imaging devices, and computing platforms. The company also provides high-capacity storage solutions, such as solid-state drives that are used in lieu of hard disk drives. It offers its products to the m obile phone, consumer electronics, and computing end markets through original equipment manufacturers, distributors, and retail sales channels in the Americas, the Asia Pacific, Europe, the Middle East, Africa, and Japan. The company was formerly known as SunDisk Corporation and changed its name to SanDisk Corporation in August 1995. SanDisk Corporation was founded in 1988 and is headquartered in Milpitas, California.
Advisors' Opinion:- [By Benjamin Pimentel]
Apple (AAPL) �shed 0.5% to close at $520.03 as the company�� new iPad Air hit the stores. Chip stocks also retreated, led by Intel Corp. (INTC) , Texas Instruments (TXN) , Advanced Micro Devices (AMD) and SanDisk (SNDK) .
Best Life Sciences Companies To Invest In Right Now: Intralinks Holdings Inc (IL)
IntraLinks Holdings, Inc. (IntraLinks), incorporated in June 1996, together with its subsidiaries, is a global provider of Software-as-a-Service (SaaS) solutions for securely managing content, exchanging critical business information and collaborating within and among organizations. The Company�� cloud-based solutions enable organizations to control, track, search and exchange time-sensitive information inside and outside the firewall, all within a secure environment. The Company provide services to enterprises and governmental agencies in over 60 countries across a variety of industries, including financial services, pharmaceutical, biotechnology, consumer, energy, industrial, legal, insurance, real estate and technology. The Company sells its solutions directly through an enterprise sales team with industry-specific expertise and indirectly through a customer referral network and channel partners. In April 2013, it acquired MergerID. Concurrently, IntraLinks acquired PE-Nexus LLC.
The Company delivers its solutions through a cloud-based model where they are available on-demand over the Internet using a multi-tenant SaaS architecture in which a single instance of its software serves all of its customers. The Company provides its customers with various services, including access to its cloud-based IntraLinks Platform, access to one or more of its intraLinks exchanges, and related customer support and other services.
The Company competes with Merrill Corporation, RR Donnelley & Sons Company, EMC Corporation and International Business Machines Corp. (IBM).
Advisors' Opinion:- [By Seth Jayson]
IntraLinks Holdings (NYSE: IL ) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), IntraLinks Holdings beat expectations on revenues and met expectations on earnings per share. - [By Lee Jackson]
IntraLinks Holdings Inc. (NYSE: IL) is a leading global software as a service (SaaS) provider of inter-enterprise content management and collaboration solutions. It recently launched Intralinks DealNexus, the largest global deal marketplace and professional network for qualified mergers and acquisitions (M&A) professionals. Intralinks DealNexus offers a secure and confidential way for dealmakers to find and engage the best buyers or capital partners, and it is used by more than 5,000 private equity firms, corporations, investment banks and advisors to intelligently connect and exchange deal opportunities. Wunderlich rates the company a stock to buy and has a $17 price objective. The consensus target is $12.The stock closed on Friday at $8.61.
Best Life Sciences Companies To Invest In Right Now: Barclays PLC(BCS)
Barclays PLC provides various financial products and services in Europe, the United States, Africa, and Asia. It offers retail and commercial banking, credit cards, investment banking, wealth management, and investment management services. The company?s products include current account and savings products, Woolwich branded mortgages, unsecured loans, protection products, general insurance, credit cards, Sharia-compliant products, installment finance and commercial property finance, commercial loans, and personal loans. It also offers money transmission, international and private banking, investment management, fiduciary, and brokerage services, as well as payment solutions and mobile banking services. In addition, the company provides fixed income, currency and commodities, foreign exchange, emerging markets, money markets, and credit services; equities, which include cash and equity derivatives and prime services; investment banking products and services that comprise fi nancial advisory, and equity and debt underwriting; and advisory services. It serves individual, commercial, corporate, institutional, retail, and mass affluent customers. The company was formerly known as Barclays Bank Limited and changed its name to Barclays PLC in January 1985. Barclays PLC was founded in 1896 and is headquartered in London, the United Kingdom.
Advisors' Opinion:- [By Hibah Yousuf]
Citing people familiar with the situation, the Wall Street Journal said Charter has held talks with Bank of America (BAC, Fortune 500), Barclays (BCS) and Deutsche Bank (DB) to help come up with financing for a Time Warner Cable bid.
- [By Sam Robson]
LONDON --�Private equity group�3i� (LSE: III ) this morning announced that it has made an offer for�Barclays' (LSE: BARC ) (NYSE: BCS ) �European infrastructure fund management business.
- [By Jesse Solomon]
Banking stocks, including Deutsche Bank (DB) and Barclays (BCS), were down in Europe after Deutsche Bank announced it was raising roughly �� billion ($11 billion) from investors to meet regulatory requirements.
Best Life Sciences Companies To Invest In Right Now: BioMarin Pharmaceutical Inc.(BMRN)
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.
Advisors' Opinion:- [By John Udovich]
Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron�� where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs�Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech�IPO Setbacks. FierceBiotech has�summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia,�slashed its asking price on 6.9 million shares to $12 a share to raise $82 million�from a range of $16 to $19 a share while�Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer,�has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming�Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its�new, patient-friendly approach for delivering inhaled nitric oxide on the - [By George Budwell]
Will BioMarin be the next orphan drugmaker to be bought out?
Over the last decade, BioMarin Pharmaceutical (NASDAQ: BMRN ) has become one of the top orphan drug specialists, making it a frequent visitor to the buyout rumor mill. Roche (NASDAQOTH: RHHBY ) was previously named as an interested party, but the company's CEO squashed that rumor, saying BioMarin was too expensive. - [By Sean Williams]
BioMarin Pharmaceuticals (NASDAQ: BMRN )
BioMarin might as well be considered a long lost sibling of Alexion, since they are both focused on developing rare orphan drugs which have practically no competition and hefty annual price tags, often in six-figures. However, whereas Alexion is profitable, BioMarin has some "'splaining to do," as Desi Arnaz used to say. Estimates in the upcoming quarter call for sales growth of just 8% to $134 million with losses expected to widen to $0.29 per share. Naglazyme's 1% sales increase last quarter didn't impress at all, so it'll need Aldurazyme to really step up if it hopes to maintain its frothy valuation.
Best Life Sciences Companies To Invest In Right Now: Career Education Corp (CECO)
Career Education Corporation, incorporated on January 5, 1994, through its colleges, schools and universities offers education to a student population of more than 75,000 students across the world in a variety of career-oriented disciplines through online, on-ground and hybrid learning program offerings. The Company operates four business units: University Schools, Career Schools, International and Transitional Schools. The Company�� institutions include, among others, American InterContinental University (AIU); Brooks Institute; Colorado Technical University (CTU); Harrington College of Design; INSEEC Group (INSEEC) Schools; International University of Monaco (IUM); International Academy of Design & Technology (IADT); Le Cordon Bleu North America (LCB), and Sanford-Brown Institutes and Colleges. In December 2013, Career Education Corp announced sale and transfer of control of its European education properties to private equity firm Apax Partners.
University Schools
The Company�� Colorado Technical University (CTU) schools collectively offer academic programs in the career-oriented disciplines of business studies, information systems and technologies, criminal justice, computer science and engineering, and health sciences in an online, classroom or laboratory setting. American InterContinental University (AIU) schools collectively offer academic programs in the career-oriented disciplines of business studies, information technologies, criminal justice and design technologies in an online, classroom or laboratory setting.
Career Schools
The Company�� Health Education includes its Sanford-Brown schools, along with Brown College, Briarcliffe College and Missouri College. These schools collectively offer academic programs in the career-oriented disciplines of health education, complemented by certain programs in business studies and information technology in a classroom, laboratory or online setting. Culinary Arts includes its Le Cordon Bleu schoo! ls in North America that collectively offer hands-on programs in the career-oriented disciplines of culinary arts and patisserie and baking in the commercial kitchens of Le Cordon Bleu, and advanced degree programs in culinary arts and hotel and restaurant management online. Design and Technology includes IADT, Harrington College of Design and Brooks Institute schools. These schools collectively offer academic programs primarily in the career-oriented disciplines of fashion design, game design, graphic design, interior design, film and video production, photography and visual communications in a classroom, laboratory or online setting, as well as jobs training in the field of energy conservation.
International
The Company�� International includes its INSEEC schools and IUM school which are located in France, the United Kingdom and Monaco. These schools collectively offer academic programs in the career-oriented disciplines of business studies, health education, advertising, communications and technologies and luxury goods and services in a classroom or laboratory setting.
Transitional Schools
The Company�� Transitional Schools includes its campuses that are being taught out. Schools that operate within this segment include Collins College, Phoenix, AZ, Colorado Technical University (CTU), CTU Pueblo, Pueblo, CO, and CTU Sioux Falls, Sioux Falls, SD.
The Company competes with Apollo Group, Bridgepoint Education, Inc., Capella Education Company, Corinthian Colleges, Inc., DeVry Inc., Education Management Corporation, Grand Canyon Education, Inc., ITT Educational Services, Kaplan and Strayer Education.
Advisors' Opinion:- [By Bill Smith]
Competition
ESI competes with many other for-profit ventures, including:
Other for-profit educators, such as: Strayer (STRA), Apollo (APOL), DeVry (DV), Capella (CPLA), Corinthian Colleges (COCO), and Career Education Corporation (CECO)Traditional colleges/universitiesCommunity colleges
Sales, EBITDA and Earnings
ESI has steadily increased revenue and earnings. In the last decade they've grown revenue at 20.8%; EBITDA at 34.4%; FCF at 22.5%, and Book Value at 8.5%. - [By Paul Ausick]
Stocks on the Move: Career Education Corp. (NASDAQ: CECO) is up 57.6% at $5.99 after selling its European properties for $305 million. NQ Mobile Inc. (NYSE: NQ) is down another 12.3% at $10.60 after yesterday�� 50% drop following a scathing report from analysts at Muddy Waters.
- [By Ben Levisohn]
Career Education Corp. (CECO) has gained 53% to $5.80 in after-hours trading after it sold its international schools to a private equity firm.
Express Scripts (ESRX) has fallen 2.7% to $62 in after-hours trading after it reported a profit of $1.08, in line with analyst forecasts, but said the fourth quarter would come in between $109 and $1.13. Analyst had forecast $1.12.
- [By Bryan Murphy]
While the given problems that are plaguing Corinthian Colleges Inc. (NASDAQ:COCO) are unique to that particular for-profit school today, the underpinnings for today's 62% implosion from COCO shares are just as big of a threat to the likes of Apollo Education Group Inc. (NASDAQ:APOL), Career Education Corp. (NASDAQ:CECO), and most other for-profit education names. In fact, those woes have been well documented for a while, and showing up each company's books for almost as long. Pictures tell the grim tale for CECO, APOL, and all the rest as effectively as any words could, so let's let the images of what's going on here do most of the talking, beginning with... Career Education Corp.
Best Life Sciences Companies To Invest In Right Now: Antares Pharma Inc (ATRS)
Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�� subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices.
In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol, for the treatment of overactive bladder. Antares also has a licensing agreement with Watson Watson Pharmaceuticals, Inc. (Watson) under which Watson will commercialize its topical oxybutynin gel 3% product in the United States and Canada. Its gel portfolio also includes Elestrin (estradiol gel) in the United States for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies.
Pressure Assisted Injection Devices
The Company�� Pressure Assisted Injection Devices consists of three products: reusable needle-free injectors, disposable pressure assisted auto injectors and disposable pen injectors. Reusable needle-free injectors deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. The injector employs a disposable pl! astic needle-free syringe, which offers liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle.
Disposable pressure assisted auto injectors is a technology of controlled pressure delivery of drugs into the body utilizing a spring power source. The Vibex is designed to provide fast subcutaneous or intramuscular injections of up to 0.5ml with minimal discomfort and improved convenience in conjunction with the enhanced safety of a shielded needle. Disposable pen injectors are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The devices contain mechanisms that specify the dose to be delivered by defining the amount of movement by the stopper in the cartridge with each device actuation.
The Vision/Tjet has been sold for use in more than 30 countries to deliver either insulin or hGH. The product features a reusable, spring-based power source and disposable needle-free syringe, which acts as the pathway for the injectable drug through the skin and allows for viewing of the medication dose prior to injection. The product is also reusable, with each device designed to last for approximately 3,000 injections (or approximately two years) while the needle-free syringe, when used with insulin or hGH, is disposable after approximately one week when used by a single patient for injecting from multi-dose vials. The Vision/Tjet administers injectables by using a spring to push the active ingredient in solution or suspension through a micro-fine opening in the needle-free syringe. The opening is approximately half the diameter of a 30-gauge needle. The Vision/Tjet is primarily used in the United States, Europe, Asia and Japan.
Antares has designed disposable, pressure assisted auto injector devices to address acute medical needs, such as allergic reactions, migraine headaches, acute pain, emesis and other daily therapies. Its Vibex disposable product combines a low-energy, spr! ing-based! power source with a hidden needle, which delivers up to 0.5ml of the needed drug solution subcutaneously or intramuscularly. Antares is also developing a Vibex MTX auto injector for delivery of methotrexate for treatment of rheumatoid arthritis. The Company�� multi use, disposable pen injector complements its portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi- dose cartridges. The disposable pen is in the stage of development where devices are being used in clinical evaluations.
Transdermal Products
The Company�� ATD system penetrates the skin to deliver a variety of treatments. The gels consist of a hydro-alcoholic base, including a combination of permeation enhancers. Products being developed/ commercialized include Anturol, Elestrin and Nestragel. Elestrin is a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. Its other injectable drugs that are presently self-administered and may be suitable for injection with its systems include therapies for the prevention of blood clots and treatments for multiple sclerosis, migraine headaches, inflammatory diseases, impotence, infertility, acquired immune deficiency symdrome (AIDS) and hepatitis.
The Company competes with Ypsomed AG, SHL Group AB, OwenMumford Ltd., West Pharmaceuticals, Becton Dickinson, Haselmeir GmbH, Elcam Medical, Vetter Pharma, Bioject Medical Technologies Inc., The Medical House PLC, Watson, Abbott, Eli Lilly, Auxillium, Inc., Endo Pharmaceuticals, Teva, Mylan, Roxane, Bedford Labs, APP Pharmaceuticals, Hospira, Pfizer, GSK/Astellas, Warner Chilcott and Allergan.
Advisors' Opinion:- [By Keith Speights]
1. Antares Pharma (NASDAQ: ATRS )
Antares has experienced a roller-coaster ride so far this year. The stock was up more than 10% early in January, then proceeded to fall by more than 20% by late February. Since then, Antares has clawed its way back and now stands up a little over 10% for the year.� - [By Monica Gerson]
Antares Pharma (NASDAQ: ATRS) shares tumbled 3.09% to touch a new 52-week low of $3.14. Antares Pharma's PEG ratio is -0.29.
eGain (NASDAQ: EGAN) shares fell 3.76% to reach a new 52-week low of $6.40. eGain's trailing-twelve-month ROE is -8.92%
- [By Keith Speights]
Antares Pharma (NASDAQ: ATRS ) announced its first-quarter results �Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.
No comments:
Post a Comment